Director Dealings and Issue of Equity

RNS Number : 6562P

MaxCyte, Inc.

19 February 2021

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

Director Dealings and Issue of Equity

Total Voting Rights

Gaithersburg, Maryland - 19 February 2021:   MaxCyte (LSE: MXCT, MXCL, MXCN), the global cell-based medicines and life sciences company, announces that Will Brooke, Non-Executive Director of the Company, has exercised options over 40,900 shares of common stock, $0.01 par, of the Company ("Common Stock") ("Exercise"). The 40,900 new shares of Common Stock issued pursuant to the Exercise ("New Common Stock") have been sold by Mr Brooke at a price of 1015 pence per Common Stock ("Sale").

Following the Exercise and Sale, Mr Brooke's holding of Common Stock remains unchanged at a total of 50,302 Common Stock, representing 0.1% of the issued share capital of the Company. Mr Brooke holds a further 128,500 options over Common Stock.

Total voting rights

The new Common Stock will be allocated out of the common stock the subject of the block listing announced on 2 May 2017. The New Common Stock will rank pari passu with the existing shares of common stock of the Company. The total issued stock capital of the Company following the issue of the New Common Stock and following the recent issue of an additional 597,877 new Common Stock to non-PDMRs in satisfaction of the exercise of share options, is 84,555,946 shares of common stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

The number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is 74,325,857 ; the number of restricted shares of Common Stock trading under the symbol 'MXCL' is  9,900,089 a nd the number of restricted shares of Common Stock trading under the symbol 'MXCN' will be 330,000.    

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Will Brooke
2	Reason for the notification
a)	Position/status	Non Executive Director
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	MaxCyte, Inc.
b)	LEI	54930053YHXULRFCU991
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Exercise of options and Sale of Common Stock
b)	Identification Code	US57777K1060
c)	Nature of the transaction	Exercise of options and Sale of Common Stock by PDMR
d)	Price(s) and volume(s)	Price(s)	Volume(s)
		N/A 1015 pence	40,900 (option exercise) 40,900 (sale of common stock)
e)	Aggregated information - Aggregated volume - Price	N/A N/A N/A
f)	Date of the transaction	18 February 2021
g)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

For further information, please contact:

MaxCyte Inc. Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Accounting Officer [phone] Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl Freddy Crossley Corporate Broking Rupert Dearden [phone] Joint Corporate Broker Numis Securities Limited James Black Duncan Monteith [phone] Joint Corporate Broker Stifel Nicolaus Europe Limited Healthcare Investment Banking Nicholas Moore / Ben Maddison / Samira Essebiyea Corporate Broking Nick Adams     [phone]

About MaxCyte

MaxCyte is a world-leading provider of cell-engineering enabling technology and is responsible for helping to bring next-generation cell and gene-editing therapies to life. The Company's technology is deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 140 cell therapy programmes, with more than 100 licensed for clinical use, and the Company has now entered into twelve clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL, MXCN) and is headquartered in Gaithersburg, Maryland, US. For more information, visit  www.maxcyte.com .

 

END

 

 

DSHTPMBTMTBBTBB